Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV MDR is still a relevant issue despite its dramatic drop over the years.
Armenia D, Di Carlo D, Flandre P, Bouba Y, Borghi V, Forbici F, Bertoli A, Gori C, Fabeni L, Gennari W, Pinnetti C, Mondi A, Cicalini S, Gagliardini R, Vergori A, Bellagamba R, Malagnino V, Montella F, Colafigli M, Latini A, Marocco R, Licthner M, Andreoni M, Mussini C, Ceccherini-Silberstein F, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: perno cf. J Antimicrob Chemother. 2020 May 1;75(5):1301-1310. doi: 10.1093/jac/dkz554. J Antimicrob Chemother. 2020. PMID: 31976521
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.
Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Armenia D, et al. Among authors: perno cf. Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309. Antivir Ther. 2019. PMID: 30977466 Free article.
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R, Borghi V, Gennari W, Cicalini S, Buonomini A, Teti E, Lanini S, Latini A, Sarmati L, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Armenia D, et al. Among authors: perno cf. J Glob Antimicrob Resist. 2022 Sep;30:326-334. doi: 10.1016/j.jgar.2022.06.027. Epub 2022 Jul 3. J Glob Antimicrob Resist. 2022. PMID: 35793776 Free article.
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.
Armenia D, Fabeni L, Alteri C, Di Pinto D, Di Carlo D, Bertoli A, Gori C, Carta S, Fedele V, Forbici F, D'Arrigo R, Svicher V, Berno G, Pizzi D, Nicastri E, Sarmati L, Pinnetti C, Ammassari A, D'Offizi G, Latini A, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM. Armenia D, et al. Among authors: perno cf. J Antimicrob Chemother. 2015;70(6):1865-73. doi: 10.1093/jac/dkv029. Epub 2015 Feb 23. J Antimicrob Chemother. 2015. PMID: 25712318 Free article.
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
Armenia D, Di Carlo D, Maffongelli G, Borghi V, Alteri C, Forbici F, Bertoli A, Gori C, Giuliani M, Nicastri E, Zaccarelli M, Pinnetti C, Cicalini S, D'Offizi G, Ceccherini-Silberstein F, Mussini C, Antinori A, Andreoni M, Perno CF, Santoro MM. Armenia D, et al. Among authors: perno cf. HIV Med. 2017 Jan;18(1):21-32. doi: 10.1111/hiv.12388. Epub 2016 Jun 28. HIV Med. 2017. PMID: 27353061 Free article.
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: perno cf. J Antimicrob Chemother. 2017 Mar 1;72(3):855-865. doi: 10.1093/jac/dkw512. J Antimicrob Chemother. 2017. PMID: 27999048
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14.
Fabeni L, Alteri C, Di Carlo D, Orchi N, Carioti L, Bertoli A, Gori C, Forbici F, Continenza F, Maffongelli G, Pinnetti C, Vergori A, Mondi A, Ammassari A, Borghi V, Giuliani M, De Carli G, Pittalis S, Grisetti S, Pennica A, Mastroianni CM, Montella F, Cristaudo A, Mussini C, Girardi E, Andreoni M, Antinori A, Ceccherini-Silberstein F, Perno CF, Santoro MM; SENDIH Study Group; SENDIH (Studio Epidemiologico Nuove Diagnosi Infezione da HIV) Study Group. Fabeni L, et al. Among authors: perno cf. J Antimicrob Chemother. 2017 Oct 1;72(10):2837-2845. doi: 10.1093/jac/dkx231. J Antimicrob Chemother. 2017. PMID: 29091206 Free article.
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.
d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group. d'Arminio Monforte A, et al. Among authors: perno cf. J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. J Antimicrob Chemother. 2020. PMID: 31865395
Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test (GRT) at National Institute for Infectious Diseases Lazzaro Spallanzani. Zaccarelli M, et al. Among authors: perno cf. AIDS. 2005 Jul 1;19(10):1081-9. doi: 10.1097/01.aids.0000174455.01369.ad. AIDS. 2005. PMID: 15958840
Historical resistance profile helps to predict salvage failure.
Zaccarelli M, Lorenzini P, Ceccherini-Silberstein F, Tozzi V, Forbici F, Gori C, Trotta MP, Boumis E, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Zaccarelli M, et al. Among authors: perno cf. Antivir Ther. 2009;14(2):285-91. Antivir Ther. 2009. PMID: 19430103
710 results